Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inR target 1
- Development stage
- Preclinical
- Lead developer
- 149 Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**inR target 1** is a preclinical-stage therapeutic candidate being developed by **149 Bio** (also known as **AllositeTx**). The program is currently focused on undisclosed indications within the **immunology and inflammation (I&I)** therapeutic area. As part of 149 Bio's pipeline, which leverages a proprietary platform for **allosteric modulation**, the asset is designed to target the **insulin receptor (INSR)** or a related signaling pathway. The drug is likely a small molecule, consistent with the developer's focus on allosteric small-molecule pharmacology, although specific molecular details and the exact mechanism of action remain proprietary.
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on inR target 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inR target 1.